“Armed” oncolytic herpes simplex viruses for brain tumor therapy

Todo, Tomoki

doi:10.4161/cam.2.3.6353

Cited by 25 publications

(23 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Immunohistochemistry revealed an infiltration of CD4 + , CD8 + T cells and macrophages in tumors treated with NV1042 [10]. The influx of lymphocytes seemed to account for the potent antitumor effects.…”

Section: Arming Hsv With Therapeutic Genesmentioning

confidence: 97%

“…G207 induces systemic anti-tumor immunity in the course of oncolytic activity. The anti-tumor immunity is associated with an increasing cytotoxic T lymphocyte activity [10]. G47 delta is a HSV-1 vector derived from G207 with an additional deletion of nonessential 47 gene.…”

Section: An Overview Of Hsvmentioning

confidence: 99%

“…Moreover, previous work from our studies and others has shown that HSV combined with radiotherapies or chemotherapies produce synergistic action [5,6]. The HSV used as oncolytic agents offer some advantages: (i) HSV infects most tumor cells types and replicates rapidly in infected cells; (ii) HSV virions have the ability of viral penetration within tumor; (iii) HSV with a large genome is easily manipulated and can be inserted multiple transgenes; (iv) HSV replication can be shut off with anti-HSV drug if required [7][8][9][10]. In this review, we will focus on the anti-tumor capability of HSV in basic research and clinical application.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Advance in herpes simplex viruses for cancer therapy

Liu

Dai

You

et al. 2013

Sci. China Life Sci.

View full text Add to dashboard Cite

Oncolytic virotherapy is an attractive approach that uses live viruses to selectively kill cancer cells. Oncolytic viruses can be genetically engineered to induce cell lyses through virus replication and cytotoxic protein expression. Herpes simplex virus (HSV) has become one of the most widely clinically used oncolytic agent. Various types of HSV have been studied in basic or clinical research. Combining oncolytic virotherapy with chemotherapy or radiotherapy generally produces synergic action with unclear molecular mechanisms. Arming HSV with therapeutic transgenes is a promising strategy and can be used to complement conventional therapies. As an efficient gene delivery system, HSV has been successfully used to deliver various immunomodulatory molecules. Arming HSV with therapeutic genes merits further investigation for potential clinical application.

show abstract

Section: Arming Hsv With Therapeutic Genesmentioning

confidence: 97%

Section: An Overview Of Hsvmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Advance in herpes simplex viruses for cancer therapy

Liu

Dai

You

et al. 2013

Sci. China Life Sci.

View full text Add to dashboard Cite

show abstract

“…HSV is not an integrating virus so it does not affect the host genome stability and it has itself a very stable DNA genome. It can infect most tumor types and has been extensively investigated in neuronal cells which are normally difficult to transduce and so brain tumor therapy can prove specifically effective using HSV (Todo, 2008a;Mineta et al, 1995). In case of adverse effects in a patient, there are many available anti-virals for HSV that can prevent or calm negative effects of infection.…”

Section: Herpes Simplex Virusesmentioning

confidence: 99%

Anticancer Gene Transfer for Cancer Gene Therapy

Pazarentzos

Mazarakis

2014

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Gene therapy vectors are among the treatments currently used to treat malignant tumors. Gene therapy vectors use a specific therapeutic transgene that causes death in cancer cells. In early attempts at gene therapy, therapeutic transgenes were driven by nonspecific vectors which induced toxicity to normal cells in addition to the cancer cells. Recently, novel cancer specific viral vectors have been developed that target cancer cells leaving normal cells unharmed. Here we review such cancer specific gene therapy systems currently used in the treatment of cancer and discuss the major challenges and future directions in this field.

show abstract

“…As such, this approach has been widely applied in preclinical models and clinical trials. oHSVs armed with immunomodulators continue to be popular among oHSV laboratories, and continue to be studied in ongoing clinical and preclinical investigations of oHSV therapy (94,96,(98)(99)(100)(101)(102)(103).…”

Section: Arming Vectors: Insertion Of Genes Encoding For Anticancer Pmentioning

confidence: 99%

Oncolytic herpes simplex virus 1 (HSV-1) vectors: Increasing treatment efficacy and range through strategic virus design

Carson¹,

Haddad²,

Bressman³

et al. 2010

Drugs Fut

View full text Add to dashboard Cite

SUMMARYViruses have long been considered potential anticancer treatments. Wild-type viruses have been tested as anticancer agents in clinical trials since the 1960s. The possibility of viral oncolysis as an alternate cancer therapy was transformed by the emergence of modern genetic engineering. The herpes simplex virus (HSV) family offers particular advantages for use as a viral oncolytic. The engineered vectors that make up oncolytic HSVs (oHSVs) have demonstrated remarkable safety in clinical trials, with some evidence of efficacy. The past decade has seen a focus on increasing the efficacy of oncolytic vectors by adding exogenous transgenes to enhance tumor destruction. The current paper describes the various strategies for engineering HSV for increased cancer tissue specificity and efficacy. Presented are the rationale, preclinical data and clinical data where available. This is meant to illustrate a basic framework for the development of a novel therapy meant to exploit the viral life cycle for the killing of cancer.

show abstract

“Armed” oncolytic herpes simplex viruses for brain tumor therapy

Cited by 25 publications

References 40 publications

Advance in herpes simplex viruses for cancer therapy

Advance in herpes simplex viruses for cancer therapy

Anticancer Gene Transfer for Cancer Gene Therapy

Oncolytic herpes simplex virus 1 (HSV-1) vectors: Increasing treatment efficacy and range through strategic virus design

Contact Info

Product

Resources

About